UCB SA - Asset Resilience Ratio
UCB SA (UCB) has an Asset Resilience Ratio of 1.21% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how UCB SA's Asset Resilience Ratio has changed over time. Check UCB capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down UCB SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of UCB SA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €219.00 Million | 1.21% |
| Total Liquid Assets | €219.00 Million | 1.21% |
Asset Resilience Insights
- Limited Liquidity: UCB SA maintains only 1.21% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
UCB SA Industry Peers by Asset Resilience Ratio
Compare UCB SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for UCB SA (2000–2025)
The table below shows the annual Asset Resilience Ratio data for UCB SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.21% | €219.00 Million ≈ $256.03 Million |
€18.16 Billion ≈ $21.23 Billion |
+0.15pp |
| 2024-12-31 | 1.06% | €184.00 Million ≈ $215.12 Million |
€17.35 Billion ≈ $20.28 Billion |
+0.37pp |
| 2023-12-31 | 0.70% | €108.00 Million ≈ $126.26 Million |
€15.54 Billion ≈ $18.17 Billion |
-0.38pp |
| 2022-12-31 | 1.07% | €170.00 Million ≈ $198.75 Million |
€15.87 Billion ≈ $18.55 Billion |
+0.30pp |
| 2021-12-31 | 0.77% | €110.00 Million ≈ $128.60 Million |
€14.21 Billion ≈ $16.61 Billion |
-4.51pp |
| 2020-12-31 | 5.29% | €704.00 Million ≈ $823.05 Million |
€13.32 Billion ≈ $15.57 Billion |
-3.64pp |
| 2019-12-31 | 8.93% | €989.00 Million ≈ $1.16 Billion |
€11.08 Billion ≈ $12.95 Billion |
+8.76pp |
| 2018-12-31 | 0.16% | €17.00 Million ≈ $19.87 Million |
€10.51 Billion ≈ $12.29 Billion |
+0.02pp |
| 2017-12-31 | 0.14% | €14.00 Million ≈ $16.37 Million |
€9.92 Billion ≈ $11.59 Billion |
-0.31pp |
| 2016-12-31 | 0.45% | €46.00 Million ≈ $53.78 Million |
€10.21 Billion ≈ $11.94 Billion |
+0.14pp |
| 2015-12-31 | 0.31% | €34.00 Million ≈ $39.75 Million |
€10.96 Billion ≈ $12.81 Billion |
+0.30pp |
| 2014-12-31 | 0.01% | €1.00 Million ≈ $1.17 Million |
€10.15 Billion ≈ $11.86 Billion |
0.00pp |
| 2013-12-31 | 0.01% | €1.00 Million ≈ $1.17 Million |
€9.76 Billion ≈ $11.41 Billion |
-0.08pp |
| 2012-12-31 | 0.09% | €8.00 Million ≈ $9.35 Million |
€9.36 Billion ≈ $10.94 Billion |
-0.33pp |
| 2011-12-31 | 0.41% | €38.00 Million ≈ $44.43 Million |
€9.18 Billion ≈ $10.73 Billion |
-0.27pp |
| 2010-12-31 | 0.68% | €61.00 Million ≈ $71.32 Million |
€8.97 Billion ≈ $10.49 Billion |
+0.10pp |
| 2009-12-31 | 0.58% | €53.00 Million ≈ $61.96 Million |
€9.12 Billion ≈ $10.66 Billion |
+0.55pp |
| 2008-12-31 | 0.03% | €3.00 Million ≈ $3.51 Million |
€9.52 Billion ≈ $11.13 Billion |
-0.97pp |
| 2007-12-31 | 1.00% | €96.00 Million ≈ $112.23 Million |
€9.55 Billion ≈ $11.17 Billion |
-6.45pp |
| 2004-12-31 | 7.45% | €400.36 Million ≈ $468.06 Million |
€5.37 Billion ≈ $6.28 Billion |
-4.17pp |
| 2003-12-31 | 11.62% | €359.05 Million ≈ $419.77 Million |
€3.09 Billion ≈ $3.61 Billion |
-4.44pp |
| 2002-12-31 | 16.05% | €420.73 Million ≈ $491.88 Million |
€2.62 Billion ≈ $3.06 Billion |
+2.83pp |
| 2001-12-31 | 13.22% | €339.05 Million ≈ $396.39 Million |
€2.56 Billion ≈ $3.00 Billion |
+1.63pp |
| 2000-12-31 | 11.59% | €266.93 Million ≈ $312.07 Million |
€2.30 Billion ≈ $2.69 Billion |
-- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more